Literature DB >> 8057151

Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors.

F F Lang1, D C Miller, M Koslow, E W Newcomb.   

Abstract

To characterize some of the genetic events underlying the development of glioblastoma multiforme, the authors analyzed 65 astrocytic tumors (seven pilocytic astrocytomas, eight astrocytomas, 16 anaplastic astrocytomas, and 34 glioblastomas multiforme) for loss of heterozygosity for chromosome 17p, loss of heterozygosity for chromosomes 10p and 10q, amplification of the epidermal growth factor receptor (EGFR) gene, and amplification of the oncogenes N-myc, c-myc, and N-ras using Southern blot analysis. Alterations of the p53 gene (positive immunostaining for p53 protein in tumors with or without p53 gene mutations) in these 65 tumors were analyzed previously. None of the 65 tumors showed amplification or rearrangement of N-myc, c-myc, or N-ras oncogenes. The molecular analysis presented here demonstrates distinct variants of astrocytic tumors, with at least three genetic pathways leading to glioblastoma multiforme. One pathway was characterized by 43 astrocytomas with alterations in p53. Glioblastomas with p53 alterations may represent tumors that progress from lower-grade astrocytomas. This variant was more likely to show loss of chromosome 17p than tumors without p53 alterations (p < 0.04). Seventy-five percent of tumors with loss of one 17p allele demonstrated mutations in the p53 gene. Loss of chromosome 10 was associated with progression from anaplastic astrocytoma (13%) to glioblastoma (38%) (p < 0.04). Amplification of the EGFR gene was a rare (7%) but late event in tumor progression (p < 0.03). A second pathway was characterized by six astrocytomas without p53 alterations and may represent clinically de novo high-grade tumors. These tumors were more likely to show amplification of the EGFR gene (83%) than tumors with p53 alterations. Sixty percent of tumors with EGFR amplification also showed loss of chromosome 10; loss of chromosome 17p was infrequent in this variant. One or more alternative pathways were characterized by 16 astrocytomas without p53 alterations and with none of the genetic changes analyzed in this study. Glioblastomas are a heterogeneous group of tumors that may arise via multiple genetic pathways.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8057151     DOI: 10.3171/jns.1994.81.3.0427

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  58 in total

Review 1.  Glioma classification: a molecular reappraisal.

Authors:  D N Louis; E C Holland; J G Cairncross
Journal:  Am J Pathol       Date:  2001-09       Impact factor: 4.307

2.  Pattern of self-organization in tumour systems: complex growth dynamics in a novel brain tumour spheroid model.

Authors:  T S Deisboeck; M E Berens; A R Kansal; S Torquato; A O Stemmer-Rachamimov; E A Chiocca
Journal:  Cell Prolif       Date:  2001-04       Impact factor: 6.831

3.  Detection of JC virus DNA sequence and expression of the viral oncoprotein, tumor antigen, in brain of immunocompetent patient with oligoastrocytoma.

Authors:  A Rencic; J Gordon; J Otte; M Curtis; A Kovatich; P Zoltick; K Khalili; D Andrews
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

4.  Deletion mapping of gliomas suggest the presence of two small regions for candidate tumor-suppressor genes in a 17-cM interval on chromosome 10q.

Authors:  R Albarosa; B M Colombo; L Roz; I Magnani; B Pollo; N Cirenei; C Giani; A M Conti; S DiDonato; G Finocchiaro
Journal:  Am J Hum Genet       Date:  1996-06       Impact factor: 11.025

Review 5.  Molecular imaging of brain tumors: a bridge between clinical and molecular medicine?

Authors:  B J Schaller; M Modo; M Buchfelder
Journal:  Mol Imaging Biol       Date:  2007 Mar-Apr       Impact factor: 3.488

6.  Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma.

Authors:  Jean-François Mineo; Anne Bordron; Marc Baroncini; Claude-Alain Maurage; Carole Ramirez; Rose-Mary Siminski; Christian Berthou; Phong Dam Hieu
Journal:  J Neurooncol       Date:  2007-06-15       Impact factor: 4.130

Review 7.  Molecular analysis of pediatric brain tumors.

Authors:  Jaclyn A Biegel; Ian F Pollack
Journal:  Curr Oncol Rep       Date:  2004-11       Impact factor: 5.075

8.  IGFBP2 is overexpressed by pediatric malignant astrocytomas and induces the repair enzyme DNA-PK.

Authors:  Oren J Becher; Katia M Peterson; Soumen Khatua; Maria R Santi; Tobey J MacDonald
Journal:  J Child Neurol       Date:  2008-10       Impact factor: 1.987

9.  The importance of genomic copy number changes in the prognosis of glioblastoma multiforme.

Authors:  Ali Arslantas; Sevilhan Artan; Ulkü Oner; Hamza Müslümanoğlu; Ramazan Durmaz; Erhan Cosan; Metin Ant Atasoy; Nurettin Başaran; Eşref Tel
Journal:  Neurosurg Rev       Date:  2003-07-04       Impact factor: 3.042

10.  Long-term survivors of glioblastoma multiforme: clinical and molecular characteristics.

Authors:  M Morita; M K Rosenblum; M H Bilsky; R A Fraser; M R Rosenfeld
Journal:  J Neurooncol       Date:  1996-03       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.